Clinical trial
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe…
NCT00267306 · Facet Biotech, Industry · Completed
Key facts
| NCT number | NCT00267306 |
|---|---|
| Title | Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis |
| Official title | A Phase 1/2, Partially Randomized, Open-Label Study of Visilizumab in Patients With Severe Ulcerative Colitis Refractory to Intravenous Corticosteroids |
| Lead sponsor | Facet Biotech, Industry |
| Collaborators | PDL BioPharma, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Severe Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Visilizumab |
| Enrollment | 144 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Dec 20, 2005 |
| Last update posted | Mar 9, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: